![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SORCS1 |
Gene summary for SORCS1 |
![]() |
Gene information | Species | Human | Gene symbol | SORCS1 | Gene ID | 114815 |
Gene name | sortilin related VPS10 domain containing receptor 1 | |
Gene Alias | hSorCS | |
Cytomap | 10q25.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B3KVZ0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114815 | SORCS1 | S014 | Human | Liver | HCC | 6.02e-18 | 7.52e-01 | 0.2254 |
114815 | SORCS1 | S015 | Human | Liver | HCC | 3.17e-08 | 3.87e-01 | 0.2375 |
114815 | SORCS1 | S016 | Human | Liver | HCC | 8.57e-24 | 8.21e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
GO:000689221 | Liver | HCC | post-Golgi vesicle-mediated transport | 77/7958 | 104/18723 | 6.14e-11 | 2.24e-09 | 77 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SORCS1 | SNV | Missense_Mutation | c.3253C>A | p.His1085Asn | p.H1085N | Q8WY21 | protein_coding | deleterious(0.03) | benign(0.277) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SORCS1 | SNV | Missense_Mutation | rs201674495 | c.1823G>A | p.Arg608Gln | p.R608Q | Q8WY21 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SORCS1 | SNV | Missense_Mutation | c.2831G>T | p.Arg944Ile | p.R944I | Q8WY21 | protein_coding | tolerated(0.28) | benign(0) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SORCS1 | SNV | Missense_Mutation | c.1946T>C | p.Phe649Ser | p.F649S | Q8WY21 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SORCS1 | SNV | Missense_Mutation | c.2657T>C | p.Val886Ala | p.V886A | Q8WY21 | protein_coding | deleterious(0.01) | probably_damaging(0.913) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SORCS1 | SNV | Missense_Mutation | c.583T>C | p.Tyr195His | p.Y195H | Q8WY21 | protein_coding | deleterious(0) | benign(0.02) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SORCS1 | SNV | Missense_Mutation | novel | c.2548N>G | p.Ser850Ala | p.S850A | Q8WY21 | protein_coding | tolerated(0.91) | benign(0.058) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SORCS1 | SNV | Missense_Mutation | novel | c.1979N>C | p.Leu660Pro | p.L660P | Q8WY21 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SORCS1 | SNV | Missense_Mutation | rs377202317 | c.2938C>T | p.Arg980Cys | p.R980C | Q8WY21 | protein_coding | deleterious(0.04) | possibly_damaging(0.731) | TCGA-D1-A17A-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SORCS1 | SNV | Missense_Mutation | c.2588G>A | p.Gly863Asp | p.G863D | Q8WY21 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A17M-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |